ASCL1 characterizes adrenergic neuroblastoma via its pioneer function and cooperation with core regulatory circuit factors

Cell Rep. 2023 Dec 26;42(12):113541. doi: 10.1016/j.celrep.2023.113541. Epub 2023 Dec 5.

Abstract

Neuroblastoma originates from developing neural crest and can interconvert between the mesenchymal (MES) and adrenergic (ADRN) states, each of which are controlled by different sets of transcription factors forming the core regulatory circuit (CRC). However, the roles of CRC factors in induction and maintenance of specific state are poorly understood. Here, we demonstrate that overexpression of ASCL1, an ADRN CRC factor, in MES neuroblastoma cells opens closed chromatin at the promoters of key ADRN genes, accompanied by epigenetic activation and establishment of enhancer-promoter interactions, initiating the ADRN gene expression program. ASCL1 inhibits the transforming growth factor β-SMAD2/3 pathway but activates the bone morphogenetic protein SMAD1-ID3/4 pathway. ASCL1 and other CRC members potentiate each other's activity, increasing the expression of the original targets and inducing a new set of genes, thereby fully inducing the ADRN program. Our results demonstrate that ASCL1 serves as a pioneer factor and cooperates with CRC factors to characterize the ADRN gene expression program.

Keywords: ASCL1; CP: Cancer; chromatin; core regulatory circuit; neuroblastoma; pioneer factor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic Agents
  • Basic Helix-Loop-Helix Transcription Factors* / genetics
  • Basic Helix-Loop-Helix Transcription Factors* / metabolism
  • Humans
  • Neuroblastoma* / genetics
  • Neuroblastoma* / metabolism
  • Promoter Regions, Genetic / genetics
  • Transcription Factors / metabolism

Substances

  • Basic Helix-Loop-Helix Transcription Factors
  • Adrenergic Agents
  • Transcription Factors
  • ASCL1 protein, human